Enveric BiosciencesENVB
13F holders, Q3 2025 (September 30)11holders −3
1new positions
4sold out
1famous investor
$0.64avg. 13F price*
At the end of Q3 2025, 11 institutions reported holding Enveric Biosciences Inc. (ENVB) in their 13F filings, down 3 from Q2 2025. 1 opened new positions and 4 sold out. The largest holders were AdvisorShares Investments LLC ($130K), UBS Group AG ($67K) and Geode Capital Management, LLC ($18K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Enveric Biosciences Inc.
- CUSIP
- 29405E406
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $14K |
| Exits | 4 | $86K |
All 13F filers, Q2 2025 → Q3 2025: 201,020 shares bought and 71,329 shares sold, net +129,691 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| AdvisorShares Investments LLC | 0.02% | Add +96.5% | 203,679 | $130K |
| UBS Group AG | 0.00% | Add +285.3% | 105,333 | $67K |
| Geode Capital Management, LLC | 0.00% | Add +1.2% | 28,510 | $18K |
| Citadel Advisors | 0.00% | New | 22,674 | $14K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -18.2% | 2,418 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 600 | $384 |
| BlackRock, Inc. | 0.00% | No change | 601 | $384 |
| Bank of America Corp. | 0.00% | Add +8.3% | 26 | $17 |
| National Bank of Canada | 0.00% | No change | 5 | $3 |
| Wells Fargo & Company | 0.00% | No change | 2 | $1 |
| Group One Trading LLC | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ENVB's weight in each manager's 13F, not the share of Enveric Biosciences Inc. the manager owns.